A Phase 3 interventional study of NCX 470 0.1% and Latanoprost 0.005% in Open Angle Glaucoma and Ocular Hypertension, sponsored by Nicox Ophthalmics, Inc.. Completed at 88 sites in 2 countries. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Nicox Ophthalmics, Inc. · Phase 3, Interventional, and Treatment
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.
This study's enrollment of 696 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Nicox Ophthalmics, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
Drug: NCX 470 0.1%
Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
Drug: Latanoprost 0.005%
NCX 470 Ophthalmic Solution, 0.1%
Also known as: NCX 470
Latanoprost Ophthalmic Solution, 0.005%
Also known as: Latanoprost
Change from baseline IOP
Mean IOP change from time-matched baseline at 8AM and 4PM time points at the Week 2, Week 6 and Month 3 Visits in the study eye
Time frame: Up to 3 months
Change from baseline in diurnal IOP
Mean diurnal IOP change from baseline at the Week 2, Week 6 and Month 3 Visits in the study eye
Time frame: Up to 3 months
Frequency and incidence of treatment-emergent adverse events
Number and percentage of subjects with ocular and non-ocular treatment-emergent adverse events
Time frame: 12 months
Rate of discontinuation
Percentage of subjects in each treatment group who discontinue study participation
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NCX 470
Nicox Ophthalmics, Inc.